Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,524 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study.
Stilgenbauer S, Leblond V, Foà R, Böttcher S, Ilhan O, Knauf W, Mikuskova E, Renner C, Tausch E, Woszczyk D, Gresko E, Lundberg L, Moore T, Morris T, Robson S, Bosch F. Stilgenbauer S, et al. Among authors: bosch f. Leukemia. 2018 Aug;32(8):1778-1786. doi: 10.1038/s41375-018-0146-5. Epub 2018 Apr 27. Leukemia. 2018. PMID: 29749403 Free PMC article. Clinical Trial.
How I treat refractory CLL.
Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Giné E, Bosch F. Montserrat E, et al. Among authors: bosch f. Blood. 2006 Feb 15;107(4):1276-83. doi: 10.1182/blood-2005-02-0819. Epub 2005 Oct 4. Blood. 2006. PMID: 16204307 Free article. Review.
Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era.
Gutiérrez-García G, Colomo L, Villamor N, Arenillas L, Martínez A, Cardesa T, García-Herrera A, Setoain X, Rodríguez S, Ghita G, Abrisqueta P, Giné E, Bosch F, Campo E, Montserrat E, López-Guillermo A. Gutiérrez-García G, et al. Among authors: bosch f. Leuk Lymphoma. 2010 Jul;51(7):1225-32. doi: 10.3109/10428194.2010.483301. Leuk Lymphoma. 2010. PMID: 20497002 Clinical Trial.
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
Wendtner CM, Hillmen P, Mahadevan D, Bühler A, Uharek L, Coutré S, Frankfurt O, Bloor A, Bosch F, Furman RR, Kimby E, Gribben JG, Gobbi M, Dreisbach L, Hurd DD, Sekeres MA, Ferrajoli A, Shah S, Zhang J, Moutouh-de Parseval L, Hallek M, Heerema NA, Stilgenbauer S, Chanan-Khan AA. Wendtner CM, et al. Among authors: bosch f. Leuk Lymphoma. 2012 Mar;53(3):417-23. doi: 10.3109/10428194.2011.618232. Epub 2011 Nov 15. Leuk Lymphoma. 2012. PMID: 21879809 Clinical Trial.
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.
Abrisqueta P, Villamor N, Terol MJ, González-Barca E, González M, Ferrà C, Abella E, Delgado J, García-Marco JA, González Y, Carbonell F, Ferrer S, Monzó E, Jarque I, Muntañola A, Constants M, Escoda L, Calvo X, Bobillo S, Montoro JB, Montserrat E, Bosch F. Abrisqueta P, et al. Among authors: bosch f. Blood. 2013 Dec 5;122(24):3951-9. doi: 10.1182/blood-2013-05-502773. Epub 2013 Oct 11. Blood. 2013. PMID: 24124086 Free article. Clinical Trial.
Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia.
González-Gascón Y Marín I, Hernández-Sanchez M, Rodríguez-Vicente AE, Puiggros A, Collado R, Luño E, González T, Ruiz-Xivillé N, Ortega M, Gimeno E, Muñoz C, Infante MS, Delgado J, Vargas MT, González M, Bosch F, Espinet B, Hernández-Rivas JM, Hernández JÁ; Grupo Español de Leucemia Linfática Crónica (GELLC) and Grupo Cooperativo Español de Citogenética Hematológica (GCECGH). González-Gascón Y Marín I, et al. Among authors: bosch f. Leuk Lymphoma. 2018 Mar;59(3):633-642. doi: 10.1080/10428194.2017.1349901. Epub 2017 Jul 21. Leuk Lymphoma. 2018. PMID: 28728469
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
Fink AM, Bahlo J, Robrecht S, Al-Sawaf O, Aldaoud A, Hebart H, Jentsch-Ullrich K, Dörfel S, Fischer K, Wendtner CM, Nösslinger T, Ghia P, Bosch F, Kater AP, Döhner H, Kneba M, Kreuzer KA, Tausch E, Stilgenbauer S, Ritgen M, Böttcher S, Eichhorst B, Hallek M. Fink AM, et al. Among authors: bosch f. Lancet Haematol. 2017 Oct;4(10):e475-e486. doi: 10.1016/S2352-3026(17)30171-0. Epub 2017 Sep 12. Lancet Haematol. 2017. PMID: 28916311 Clinical Trial.
1,524 results